Tools
Tools
Bakowski, Malina A, Shiroodi, Roohollah Kazem, Renhe, Liu, Olejniczak, Jason, Yang, Baiyuan, Gagaring, Kerstin, Guo, Hui, White, Pamela M., Chappell, Laura, Debec, Alain, Landmann, Frédéric, Dubben, Bettina, Lenz, Franziska, Struever, Dominique, Ehrens, Alexandra, .Frohberger, Stefan J, Sjoberg, Hanna, Pionnier, Nicolas 
ORCID: https://orcid.org/0000-0002-2379-4945, Murphy, Emma ORCID: https://orcid.org/0000-0001-9421-7777, Archer, John, Steven, Andrew, Chunda, Valerine C., Fombad, Fanny F, Chounna, Patrick W., Njouendou, Abdel J., Metug, Haelly M., Ndzeshang, Bertrand L., Gandjui, Narcisse V., Desmond N. Akumtoh, Desmond N., Kwenti, Tayong D. B., Woods, Ashley K., Joseph, Sean B., Hull, Mitchell V., Xiong, Wen, Kuhen, Kelli L., Taylor, Mark ORCID: https://orcid.org/0000-0003-3396-9275, Wanji, Samuel, Turner, Joseph ORCID: https://orcid.org/0000-0002-2185-5476, Hübner, Marc P., Hoerauf, Achim, Roland, Jason, Tremblay, Matt S., Schultz, Peter G, Sullivan, William, Chu, Xin-Jie, Petrassi, Michael and McNamara, Case W.
(2019)
'Discovery of short-course antiwolbachial quinazolines for elimination
of filarial worm infections'. Science Translational Medicine, Vol 11, Issue 491, eaav3523.
|
Text
aav3523_CombinedPDF_v7.pdf - Accepted Version Download (1MB) | Preview |
Abstract
Parasitic filarial nematodes cause debilitating infections in people in resource-limited countries. A clinically validated approach to eliminate worms uses a 4–6 week course of doxycycline that targets Wolbachia, a bacterial endosymbiont required for worm viability and reproduction. However, the prolonged length of therapy and contraindication in children and pregnant women have slowed adoption of this treatment. Here we describe discovery and optimization of quinazolines CBR417 and CBR490 that with a single dose achieve > 99% elimination of Wolbachia in the in vivo Litomosoides sigmodontis filarial infection model. The efficacious quinazoline series was identified by pairing a primary cell-based high content imaging screen with an orthogonal ex vivo validation assay to rapidly quantify Wolbachia elimination in Brugia pahangi filarial ovaries. We screened 300,368 small molecules in the primary assay and identified 288 potent and selective hits. Of 134 primary hits tested, only 23.9% were active in the worm-based validation assay, eight of which contained a quinazoline heterocycle core. Medicinal chemistry optimization generated quinazolines with excellent pharmacokinetic profiles in mice. Potent anti-wolbachial activity was confirmed in L. sigmodontis, B. malayi, and Onchocerca ochengi in vivo preclinical models of filarial disease, and in vitro selectivity against Loa loa (a safety concern in endemic areas). The favorable efficacy and in vitro safety profiles of CBR490 and CBR417 further support these as clinical candidates for treatment of filarial infections.
| Item Type: | Article |
|---|---|
| Subjects: | QW Microbiology and Immunology > Bacteria > QW 131 Gram-negative bacteria. WA Public Health > Preventive Medicine > WA 110 Prevention and control of communicable diseases. Transmission of infectious diseases WC Communicable Diseases > Tropical and Parasitic Diseases > WC 680 Tropical diseases (General) WC Communicable Diseases > Tropical and Parasitic Diseases > WC 880 Filariasis and related conditions (General) WR Dermatology > Parasitic Skin Diseases > WR 360 Skin diseases caused by arthropods (General or not elsewhere classified) |
| Faculty: Department: | Biological Sciences > Department of Tropical Disease Biology |
| Digital Object Identifer (DOI): | https://doi.org/10.1126/scitranslmed.aav3523 |
| Depositing User: | Stacy Murtagh |
| Date Deposited: | 09 May 2019 11:29 |
| Last Modified: | 01 Nov 2021 12:29 |
| URI: | https://archive.lstmed.ac.uk/id/eprint/10524 |
Statistics
Actions (login required)
 |
Edit Item |